Saracatinib in Treating Patients With Prostate Cancer

Stopped Per protocol, study was terminated due to low rate of randomized patients.

Conditions

• Hormone-resistant Prostate Cancer
• Recurrent Prostate Cancer
• Stage IV Prostate Cancer

Interventions

• DRUG: saracatinib
• OTHER: hydrocortisone/placebo

Sponsor

National Cancer Institute (NCI)